Connect with us

Health

BioNTech co-founders leave to focus on next-generation mRNA innovation

SHARE:

Published

4 months ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The co-founders of BioNTech, married couple, Professors Ugur Sahin and Özlem Türec, today (10 March) announced plans to step down from BioNTech leadership roles and establish an independent company to develop next-generation mRNA innovations with disruptive potential. Sahin and Türeci will transition to managing their new company by the end of 2026.

BioNTech will continue to focus on its late-stage pipeline spanning innovative immunomodulator, antibody-drug conjugate (“ADC”), mRNA candidates and its COVID-19 vaccine franchise. BioNTech has 15 ongoing Phase 3 clinical trials in oncology.

“Over the past 18 years, we have built BioNTech from a start-up into a global biopharmaceutical company with a strong and diversified pipeline. During...

Share this article:

Share this:
Related Topics:
Guest Contributor - Opinion

Opinions expressed are purely those of the author and not endorsed by EU Reporter. The article was unsolicited by EU Reporter, and the author guarantees the truthfulness of the contents of the article. No payment was made by EU Reporter to the author

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending